Business, energy, technology, markets and global industry news from Business News Today

ANCA-associated vasculitis

PharmaDeviceNews ANCA-associated vasculitis
Representative image of autoimmune disease drug safety review as Amgen’s Tavneos scrutiny puts ANCA vasculitis treatment, FDA approval standards, liver risk, and rare disease evidence under sharper focus.
Pharma & Biotech

Amgen turns to Duke as FDA scrutiny puts Tavneos rare autoimmune disease role at risk

Find out how Amgen’s Tavneos data review could shape FDA withdrawal risk, liver safety scrutiny, and ANCA vasculitis care.

Read More
Pharma & Biotech

How InflaRx N.V. plans to challenge avacopan in ANCA-associated vasculitis with izicopan

InflaRx N.V. is expanding izicopan into renal inflammation and vasculitis markets. Discover what this means for complement inhibitor competition.

Read More